SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / Medical2022 Biotech Charity Contest


Previous 10 Next 10 
To: Arthur Radley who wrote (228)12/29/2022 1:56:11 PM
From: technetium
   of 267
 
I own RVNC and am not at all happy that they are tanking AFTER FDA approval. :-(

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: technetium who wrote (237)12/29/2022 2:40:51 PM
From: Arthur Radley
   of 267
 
There had been no place to hide in biotech investing in 2022. Today’s report about th collusion between the FDA and Biogen and their Alzheimer drug isn’t going to help.
How does it look for the numbers for those signed up for 2023?

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: Arthur Radley who wrote (238)12/29/2022 4:36:06 PM
From: technetium
   of 267
 
Almost nobody has signed up yet. GET WITH IT FOLKS! Thanks.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Arthur Radley who wrote (238)12/29/2022 4:43:19 PM
From: technetium
   of 267
 
Investigation faults FDA, Biogen for Alzheimer’s drug approval

washingtonpost.com

The biotechnology company Biogen and its regulator, the Food and Drug Administration, worked in concert, ignoring internal concerns from the company and skirting the agency’s own written guidance, to allow the Alzheimer’s treatment Aduhelm to receive accelerated approval and hit the market at a cost to patients of $56,000 a year, according to a scathing report released Thursday by two House committees.

“The “unusual” collaboration, which resurrected Aduhelm three months after Biogen had canceled clinical trials, unfolded through at least 115 meetings, calls and email exchanges between the company and the FDA in a year, said the report by the Committees on Oversight and Reform, and Energy and Commerce.

“The joint effort climaxed with staff from the agency helping Biogen draft a document used to brief the FDA’s advisory committee before it met to discuss Aduhelm on Nov. 6, 2020. Although the FDA often follows an advisory committee’s recommendation, it did not this time. After no member of the advisory committee recommended Aduhelm, the FDA changed course, allowing Biogen to move its drug to an accelerated approval process.

“At the FDA’s suggestion, the drug was labeled for use by the nation’s more than 6 million Alzheimer’s patients, even though it had been tested only on people with early Alzheimer’s and mild symptoms, the report said...

“… Aduhelm proved to be a financial dud, generating $3 million in revenue for all of 2021.

”In a statement responding to the report, Biogen said it had cooperated with the committees and “stands by the integrity of the actions we have taken.” Biogen’s statement also cited the FDA’s internal investigation, which concluded that there was no evidence of impropriety in the dealings between the agency and company.

“Biogen stuck with the initial $56,000-per-year price tag despite projections that the drug could wind up costing Medicare up to $12 billion in a single year. Other Alzheimer’s treatments sell for much less. A year’s supply of Aricept costs less than $8,000; Exelon, a drug in the same family, costs about $8,800 for a year’s supply; and Namenda costs less than $3,000 per year...”

Share RecommendKeepReplyMark as Last Read


To: technetium who wrote (239)12/29/2022 8:53:28 PM
From: Steve Lokness
1 Recommendation   of 267
 
Ahhh? Where to sign up?

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: Steve Lokness who wrote (241)12/29/2022 9:09:36 PM
From: Arthur Radley
   of 267
 
Steve, send him a PM.
Hope all is well in your neck of the woods and you and the family had a great holiday.
I’ve been reading about your area, the heavy flooding and power outage due to vandals. Tonight we are getting heavy rains sent from the west coast..we expect it will rain all night. Four days of sub-freezing temps and now 70 degree temps and local flooding. But we all know that global warming is a hoax.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Arthur Radley who wrote (242)12/30/2022 10:11:15 AM
From: Steve Lokness
   of 267
 
<<<<<<But we all know that global warming is a hoax.>>>>>

We are use to rain and flooding here on the Olympic Peninsula but our recent tides were almost 2 feet higher than expected. Not inches - feet! By far the highest tide I have seen here at the house.

There will be a contest then? I have seen no messages - no hype. I'd like to enter after missing a year.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Steve Lokness who wrote (243)12/30/2022 12:22:26 PM
From: Arthur Radley
   of 267
 
Look at the east coast of Florida the tidal erosion is eating away the beaches and next are the condos.

I have submitted my names and I think he plans to consolidate and organize the entries and then create the website. Sort of fun to see how bad one can do in a contest and this year I'm looking at most of mine down more than 50%---one is down 80%.

Share RecommendKeepReplyMark as Last Read


From: Aloner12/30/2022 4:56:18 PM
1 Recommendation   of 267
 
My 2023 Picks. I believe I came in close to dead last this year, so, I'll be the first to post this year! You may want to avoid these as my track record speaks volumes...
Thank you TECHNETIUM for all that you do to make the contest happen.
Here are my 10 picks, all equally weighted.

AFMD 10%
CDTX 10%
CLSD 10%
CRDF 10%
CRIS 10%
CRVS 10%
KZIA 10%
MGTA 10%
MRNA 10%
PRVB 10%

Share RecommendKeepReplyMark as Last Read


To: technetium who wrote (233)12/30/2022 5:58:17 PM
From: technetium
   of 267
 
And at the wire …. it’s GENEGURU running away from the pack. A detailed report to follow.

GLYC came through at the end.

Now remember, you’ve got only a few more days to get your new portfolios in. Next year HAS to be better. Special offer, submitters of portfolios for the 2023 Contest can request a YTD breakdown of performance of the individual choices in 2022.

Thanks to everyone who participated in this contest.

Happy New Year!!




Report Time Ranges





From

To

Recent

12/23/22

12/30/22

YTD

12/31/2021

Index Performance



Symbol

Recent

YTD



^IXIC

-0.30%

-33.10%

^NBI

-0.12%

-10.91%

^SPSIBI

2.71%

-25.71%

Share Performance

Recent Change as % of Initial Price

YTD

Top 5

Bottom 5

Top 5

Bottom 5

GLYC

52.778%

SNGX

-29.27%

MACK

193.09%

GNCA

-99.99%

PDSB

42.346%

AMRS

-7.58%

CABA

144.06%

PLXP

-97.95%

MACK

27.877%

RVNC

-7.05%

WVE

122.93%

CLVS

-97.00%

OCUP

27.346%

IPIX

-6.00%

FENC

118.18%

ATHX

-96.27%

VKTX

20.652%

DYN

-5.55%

CBIO

113.07%

OTIC

-95.81%

Top Ten Portfolios



Top 10 Portfolio YTD

YTD(Portfolio - SPSIBI)

Rec

Rec(Port. - SPSIBI)

Rec. Change Total Value

GENEGURU

19.89%

45.61%

14.05%

11.345%

$14774.05

DIEGOSAN

2.74%

28.45%

-0.27%

-2.975%

-$274.18

MOPGCW

-2.01%

23.70%

8.99%

6.277%

$8079.59

BMAZ001

-11.23%

14.48%

12.01%

9.304%

$9520.49

TECHNETIUM

-18.35%

7.36%

1.96%

-0.751%

$1568.15

BRENDAN_49

-20.04%

5.67%

4.34%

1.636%

$3329.50

BIO-TITAN

-23.39%

2.32%

24.81%

22.097%

$15226.73

RAJU_BIJLEE

-24.77%

0.94%

3.46%

0.748%

$2513.83

ROCKY9

-25.80%

-0.09%

5.19%

2.482%

$3661.71

TAMBORELLI

-25.96%

-0.24%

11.53%

8.819%

$7653.70

Average and Median Portfolio Performance



Avg Recent

Avg YTD

Median Recent

Median YTD



$3,795

-32.88%

RAJU_BIJLEE

$2,598

JFM WINTER

-32.22%

6.16%

RAJU_BIJLEE

3.901%

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10